| Type 2 Diabetes Mellitus |
1 |
1 |
| Hypoglycemia |
0 |
0.64 |
| Receptors |
0 |
0.42 |
| Indiana |
0 |
0.35 |
| Renal Disease |
0 |
0.24 |
| Chronic Kidney Disease |
0 |
0.22 |
| End-Stage Renal Disease |
0 |
0.22 |
| Obesity |
0 |
0.22 |
| Type 1 Diabetes Mellitus |
0 |
0.22 |
| Insulin Therapy |
0 |
0.21 |
| Cardiovascular Risk Management |
0 |
0.18 |
| Coronary Artery Disease (CAD) |
0 |
0.15 |
| Body Mass Index |
0 |
0.14 |
| Clinical Guidelines |
0 |
0.14 |
| Electronic Health Record (EHR) |
0 |
0.14 |
| Electronic Medical Record |
0 |
0.14 |
| Heart Failure (HF) |
0 |
0.14 |
| Hyperglycemia |
0 |
0.14 |
| Social Determinants of Health |
0 |
0.14 |
| Weight Loss |
0 |
0.14 |
| Weight Management |
0 |
0.14 |
| Renal Failure |
0 |
0.13 |
| Abdominal Pain |
0 |
0.12 |
| Pain Management |
0 |
0.12 |
| Abdomen |
0 |
0.07 |
| Adherence |
0 |
0.07 |
| Adverse Effects |
0 |
0.07 |
| Amputation |
0 |
0.07 |
| Blindness |
0 |
0.07 |
| Board Certification |
0 |
0.07 |
| Cardiovascular disease |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Diabetes Mellitus |
0 |
0.07 |
| Diarrhea |
0 |
0.07 |
| Diversity |
0 |
0.07 |
| DPP-4 Inhibitors |
0 |
0.07 |
| Drug Reaction |
0 |
0.07 |
| Endocrinology |
0 |
0.07 |
| Exercise |
0 |
0.07 |
| Genetics |
0 |
0.07 |
| Genomic Medicine |
0 |
0.07 |
| Health Administration |
0 |
0.07 |
| Health Care Economics |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Heart |
0 |
0.07 |
| Hemoglobin |
0 |
0.07 |
| Incretin Hormone |
0 |
0.07 |
| Kidney |
0 |
0.07 |
| Nausea |
0 |
0.07 |
| Pain |
0 |
0.07 |
| Patient Safety |
0 |
0.07 |